KNSA: Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Company Profile & Statistics

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Profile

About

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa Pharmaceuticals International plc is based in LONDON.

Info & Links

CEO

Sanj K. Patel

Headquarters

105 Piccadilly, Second Floor
London, X0 W1J 7NJ, UNITED KINGDOM

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

366

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Statistics

Valuation Measures

Market Capitalization²

3.51B

Enterprise Value

3.34B

Enterprise Value/EBITDA(ttm)

42.43

Price to Earnings Ratio(ttm)

62.22

Price to Sales(ttm)

5.20

Price to Book(mrq)

6.19

Price to Cash(ytd)

58.00

Profitability

Gross Margin(ttm)

88.40%

Operating Margin(ttm)

8.71%

Profit Margin(ttm)

8.70%

Return on Equity(ttm)

11.48%

Return on Invested Capital(ttm)

11.41%

Return on Assets(ttm)

8.63%

Income Statement

Revenue(ttm)

677.56M

Revenue Per Share(ttm)

8.85

Gross Profit(ttm)

599.89M

EBITDA(ttm)³

78.78M

Net Income Available to Common(ttm)

59.01M

Diluted EPS(ttm)

0.74

Share Statistics

Beta (5Y Monthly)

0.06

52-Week Change

95.81%

S&P 500 52-Week Change

15.40%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

76.54M

Dividend Yield

0.00%

Float⁴

35.60M

% Held by Insiders

53.48%

% Held by Institutions

53.95%

Balance Sheet

Total Cash(mrq)

414.07M

Total Cash Per Share(mrq)

5.41

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.79%

Quick Ratio(mrq)

3.39%

Book Value Per Share(mrq)

7.44

Cash Flow

Operating Cash Flow Per Share(ytd)

1.75

Free Cash Flow(ytd)

136.42M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

KNSA

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares